This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Ebselen
- DrugBank Accession Number
- DB12610
- Background
Ebselen has been investigated for the treatment and basic science of Meniere's Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Ebselen (DB12610)
- Weight
- Average: 274.192
Monoisotopic: 274.984936 - Chemical Formula
- C13H9NOSe
- Synonyms
- Ebselen
- ebseleno
- External IDs
- DR-3305
- DR3305
- SPI-1005
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UBifunctional epoxide hydrolase 2 inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Abciximab. Acebutolol Ebselen may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Ebselen. Acemetacin The risk or severity of adverse effects can be increased when Ebselen is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Acenocoumarol. Acetaminophen The risk or severity of adverse effects can be increased when Acetaminophen is combined with Ebselen. Acetohexamide The protein binding of Acetohexamide can be decreased when combined with Ebselen. Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ebselen. Alclofenac The risk or severity of adverse effects can be increased when Ebselen is combined with Alclofenac. Alendronic acid The risk or severity of adverse effects can be increased when Ebselen is combined with Alendronic acid. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Agents that produce hypertension
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Anti-Ulcer Agents
- Antioxidants
- Antirheumatic Agents
- Biological Factors
- Central Nervous System Agents
- Compounds used in a research, industrial, or household setting
- Cyclooxygenase Inhibitors
- Enzyme Inhibitors
- Gastrointestinal Agents
- Heterocyclic Compounds, Fused-Ring
- Neuroprotective Agents
- Peripheral Nervous System Agents
- Protective Agents
- Selenium Compounds
- Sensory System Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Not Available
- Direct Parent
- Benzene and substituted derivatives
- Alternative Parents
- Selenazoles / Heteroaromatic compounds / Lactams / Azacyclic compounds / Organoselenium compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
- Substituents
- 1,2-selenazole / Aromatic heteropolycyclic compound / Azacycle / Heteroaromatic compound / Hydrocarbon derivative / Lactam / Monocyclic benzene moiety / Organic nitrogen compound / Organic oxide / Organic oxygen compound
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- benzoselenazole (CHEBI:77543)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 40X2P7DPGH
- CAS number
- 60940-34-3
- InChI Key
- DYEFUKCXAQOFHX-UHFFFAOYSA-N
- InChI
- InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H
- IUPAC Name
- 2-phenyl-2,3-dihydro-1,2-benzoselenazol-3-one
- SMILES
- O=C1N([Se]C2=CC=CC=C12)C1=CC=CC=C1
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Menière's Disease / Ménière 1 2 Completed Prevention Temporary Auditory Threshold Shift 1 2 Completed Treatment Bipolar Disorder (BD) / Bipolar Disorder, Manic 1 2 Completed Treatment Menière's Disease 1 2 Enrolling by Invitation Treatment Coronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus 2 2 Enrolling by Invitation Treatment Ototoxicity 1 2 Unknown Status Treatment Head And Neck Cancer / Hearing loss or impairment / Lung Cancer / Neuropathy / Ototoxicity / Tinnitus 1 2 Unknown Status Treatment Hearing Loss, Noise-Induced 1 2, 3 Completed Basic Science Type 1 Diabetes Mellitus / Type 2 Diabetes Mellitus 1 1 Completed Treatment Cancer / Hearing loss or impairment 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 4.35 mg/mL ALOGPS logP 1.91 ALOGPS logP 2.65 Chemaxon logS -1.8 ALOGPS pKa (Strongest Basic) -5.1 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 20.31 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 71.54 m3·mol-1 Chemaxon Polarizability 23.06 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- Curator comments
- irreversible inhibitor of soluble epoxide hydrolase (sEH)
- General Function
- Toxic substance binding
- Specific Function
- Bifunctional enzyme. The C-terminal domain has epoxide hydrolase activity and acts on epoxides (alkene oxides, oxiranes) and arene oxides. Plays a role in xenobiotic metabolism by degrading potenti...
- Gene Name
- EPHX2
- Uniprot ID
- P34913
- Uniprot Name
- Bifunctional epoxide hydrolase 2
- Molecular Weight
- 62615.22 Da
References
- Morisseau C, Sahdeo S, Cortopassi G, Hammock BD: Development of an HTS assay for EPHX2 phosphatase activity and screening of nontargeted libraries. Anal Biochem. 2013 Mar 1;434(1):105-11. doi: 10.1016/j.ab.2012.11.017. Epub 2012 Dec 3. [Article]
Drug created at October 20, 2016 23:12 / Updated at February 21, 2021 18:53